08:33 AM EDT, 07/17/2025 (MT Newswires) -- Keros Therapeutics ( KROS ) said Thursday that a first patient was dosed in a phase 3 trial of elritercept, triggering a $10 million milestone from Takeda (TAK).

Elritercept is being developed for the treatment of adults with transfusion-dependent anemia with very low, low, or intermediate risk myelodysplastic syndromes, Keros Therapeutics ( KROS ) said.

Keros Therapeutics ( KROS ) had signed a global license agreement with Takeda in January to develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau, the company said.

Keros said it received $200 million upfront in February and is eligible to receive milestones potentially exceeding $1.1 billion as well as tiered royalties on net sales.

Shares of Keros Therapeutics ( KROS ) were up 2.5% while Takeda shares were edging 0.8% higher in recent premarket activity.